The exploration of BRCA1 and BRCA2 as well as homologous recombination deficient (HRD) has driven the development of targeted therapy for HRD, particularly poly (ADP-ribose) polymerase (PARP) inhibitors. The gene discussed is BRCA2; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.